- Home
- NCL vs CASI Comparison
NCL vs CASI Comparison
Compare NCL & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- CASI
- Stock Information
- Founded
- NCL 2013
- CASI 1991
- Country
- NCL United States
- CASI China
- Employees
- NCL N/A
- CASI N/A
- Industry
- NCL
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- CASI Health Care
- Exchange
- NCL Nasdaq
- CASI Nasdaq
- Market Cap
- NCL 30.7M
- CASI 35.8M
- IPO Year
- NCL 2023
- CASI 1996
- Fundamental
- Price
- NCL $0.12
- CASI $1.84
- Analyst Decision
- NCL
- CASI Strong Buy
- Analyst Count
- NCL 0
- CASI 1
- Target Price
- NCL N/A
- CASI $4.00
- AVG Volume (30 Days)
- NCL 2.6M
- CASI 305.0K
- Earning Date
- NCL 11-18-2025
- CASI 11-13-2025
- Dividend Yield
- NCL N/A
- CASI N/A
- EPS Growth
- NCL N/A
- CASI N/A
- EPS
- NCL N/A
- CASI N/A
- Revenue
- NCL $12,009,378.00
- CASI $31,564,000.00
- Revenue This Year
- NCL N/A
- CASI N/A
- Revenue Next Year
- NCL N/A
- CASI N/A
- P/E Ratio
- NCL N/A
- CASI N/A
- Revenue Growth
- NCL N/A
- CASI 36.64
- 52 Week Low
- NCL $0.12
- CASI $1.09
- 52 Week High
- NCL $1.52
- CASI $7.50
- Technical
- Relative Strength Index (RSI)
- NCL 47.66
- CASI 51.04
- Support Level
- NCL $0.12
- CASI $1.77
- Resistance Level
- NCL $1.03
- CASI $2.08
- Average True Range (ATR)
- NCL 0.02
- CASI 0.20
- MACD
- NCL 0.03
- CASI 0.02
- Stochastic Oscillator
- NCL 0.99
- CASI 71.84
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.